NewAmsterdam Pharma Company N.V.
NAMSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. At a $2.36B market cap, NewAmsterdam Pharma Company N.V. ranks as a mid-cap company within healthcare. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Market Cap
$2.36B
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
-12.87
EPS (TTM)
$-1.97
EPS (Fwd)
$-1.53
ROE
-36.8%
ROA
-20.1%
Cash
$633.9M
Total Debt
$82,000
Free CF
-$45.4M
52W Change
-44.8%
Annual Financials
Cash vs Debt
Where NAMS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NAMS finished 30.61% below its 150-day moving average ($29.50) and 32.64% below its 200-day moving average ($30.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NAMS overbought or oversold?
At the October 20, 2026 close, NAMS's RSI(14) was 27.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $633.9M in cash and $82K in debt, NAMS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$45.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -36.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $102.7M (2022) to $22.5M (2025), a 78% decline worth watching.
With a beta below 0.7, NewAmsterdam Pharma Company N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NewAmsterdam Pharma Company N.V.'s trajectory.